Washington Trust Advisors, Inc. Dyne Therapeutics, Inc. Transaction History
Washington Trust Advisors, Inc.
- $1.06 Billion
- Q2 2024
A detailed history of Washington Trust Advisors, Inc. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 125 shares of DYN stock, worth $4,345. This represents 0.0% of its overall portfolio holdings.
Number of Shares
125
Previous 125
-0.0%
Holding current value
$4,345
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$279 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$273 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$257 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$222 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$210 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.8B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...